ClassID:

21050

A61K38/55 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof Protease inhibitors

Sub-classes:
Recent Application in this class:
#1
20260125665
2026-05-07

TARGETING AND LYSING MICROTHROMBI ASSOCIATED WITH ABERRANT BLOOD CLOTTING

#2
20260125640
2026-05-07

ACELLULAR PLACENTAL PREPARATIONS

#3
20250387453
2025-12-25

Methods and Compositions for Treating Diabetes

#4
20250360224
2025-11-27

SYSTEMS AND METHODS FOR GENETIC MODULATION TO TREAT LIVER DISEASE

#5
20250228922
2025-07-17

METHODS FOR TREATMENT OF DISEASES

#6
20250188434
2025-06-12

METHODS AND COMPOSITIONS FOR INHIBITING ADAM9 BIOLOGICAL ACTIVITIES

#7
20250170227
2025-05-29

CONJUGATED C1 ESTERASE INHIBITOR AND USES THEREOF

#8
20250161419
2025-05-22

SERPIN PEPTIDES AND METHODS OF USING THE SAME

#9
20250135107
2025-05-01

DEVICE, SYSTEM AND METHODS FOR THE ORAL DELIVERY OF THERAPEUTIC COMPOUNDS

#10
20250099422
2025-03-27

COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATORY CONDITIONS

#11
20250082689
2025-03-13

COMPOSITIONS AND METHODS FOR ENHANCING CARDIOMYOCYTE TRANSPLANT ENGRAFTMENT

#12
20250057927
2025-02-20

ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

#13
20240408240
2024-12-12

TREATMENT OF HEREDITARY ANGIOEDEMA WITH AAV GENE THERAPY VECTORS AND THERAPEUTIC FORMULATIONS

#14
20240408185
2024-12-12

DPP-4 INHIBITOR AND PRODUCTION METHOD THEREFOR

#15
20240398904
2024-12-05

FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS

#16
20240366731
2024-11-07

ORAL ALGAL OIL BASED GASTRO-INTESTINAL TRACT PERMEABLE PEPTIDE COMPOSITION

#17
20240360200
2024-10-31

KLK5 INHIBITORY PEPTIDE

#18
20240350597
2024-10-24

PROTEASE INHIBITORS

#19
20240299503
2024-09-12

Methods and Compositions for Treating Diabetes

#20
20240285701
2024-08-29

COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS

#21
20240207377
2024-06-27

ALPHA-1-ANTITRYPSIN (AAT) IN THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL DISORDERS

#22
20240181024
2024-06-06

TREATING RESPIRATORY INFECTIONS

#23
20240181020
2024-06-06

TREATMENT OF HYPOPARATHYROIDISM

#24
20240181018
2024-06-06

Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof

#25
20240166990
2024-05-23

METHODS AND COMPOSITIONS FOR INCREASING PROTEIN EXPRESSION IN GENETICALLY ENGINEERED BACTERIA

#26
20240150318
2024-05-09

PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS

#27
20240108702
2024-04-04

Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection

#28
20240108686
2024-04-04

DPEP-1 Binding Compositions and Methods of Use

#29
20240091326
2024-03-21

Treatment of Glaucoma by Neuroprotection

#30
20240082488
2024-03-14

Device, system and methods for the oral delivery of therapeutic compounds

#31
20240000907
2024-01-04

INHIBITORS FOR USE IN TREATING LIVER DISORDERS

#32
20240000863
2024-01-04

Skin Probiotics

#33
20230414704
2023-12-28

Compositions Containing a Pharmacophore with Selectivity to Diseased Tissue and Methods of Making Same

#34
20230364158
2023-11-16

METHODS AND MATERIALS FOR TREATING GASTROINTESTINAL DISORDERS

#35
20230355727
2023-11-09

TREATMENT OF RETINAL DISORDERS

#36
20230338529
2023-10-26

COMPOSITIONS FOR ALTERING A MICROGLIAL CELL, AND METHODS OF USE THEREFORE

#37
20230285524
2023-09-14

USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN

#38
20230277636
2023-09-07

Composition comprising highly-concentrated Alpha1 proteinase inhibitor and method for obtaining thereof

#39
20230241189
2023-08-03

Compositions and Methods for Treating Granulomatosis with Polyangiitis

#40
20230233510
2023-07-27

CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS

#41
20230210956
2023-07-06

METHODS AND COMPOSITIONS FOR TREATING DIABETES

#42
20230210920
2023-07-06

METHODS AND COMPOSITIONS USING SERPIN PRODUCING BACTERIA

#43
20230190894
2023-06-22

Methods for treating pulmonary disease using inter-alpha inhibitor proteins

#44
20230190774
2023-06-22

METHOD OF USING SUBSTRATES OF AKR1Bl/AKR1B10 AS ANTI-CANCER DRUGS

#45
20230181703
2023-06-15

COMPOSITION COMPRISING PEPSTATIN AND ALGINIC ACID OR A SALT THEREOF, AND USE THEREOF

#46
20230158081
2023-05-25

EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF

#47
20230146680
2023-05-11

METHOD FOR PRODUCING ENHANCED ANTI-INFLAMMATORY / ANTI-CATABOLIC AGENTS FROM AUTOLOGOUS PHYSIOLOGICAL FLUID

#48
20230139230
2023-05-04

EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF

#49
20230127694
2023-04-27

NEUROPROTECTIVE PEPTIDE

#50
20230110157
2023-04-13

Compositions and methods for treating allergic inflammatory conditions

#51
20230024012
2023-01-26

Protease inhibitors for treatment of coronavirus infections

#52
20230023070
2023-01-26

Therapy for the Treatment of Cancer

#53
20220401495
2022-12-22

ACELLULAR PLACENTAL THERAPIES FOR NECROTIZING ENTEROCOLITIS

#54
20220389377
2022-12-08

TREATMENT OF MEDICAL CONDITIONS BY STEM CELL TRANSPLANTS AND STEM CELL ACTIVATION

#55
20220387565
2022-12-08

Ocular delivery of cell permeant therapeutics for the treatment of retinal edema

#56
20220306725
2022-09-29

KLK5 inhibitory peptide

#57
20220296688
2022-09-22

TARGETING CAPN9/CAPNS2 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES

#58
20220267412
2022-08-25

OXIDATION-RESISTANT SERPINS

#59
20220265786
2022-08-25

METHODS OF IMPROVING ORGAN FUNCTION

#60
20220193209
2022-06-23

COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION

#61
20220143133
2022-05-12

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

#62
20220133867
2022-05-05

USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN

#63
20220111021
2022-04-14

USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN

#64
20220016224
2022-01-20

METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONS

#65
20220000992
2022-01-06

Composition comprising highly-concentrated α1 proteinase inhibitor and method for obtaining thereof

#66
20220000986
2022-01-06

Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof

#67
20210369822
2021-12-02

METHODS FOR TREATMENT OF DISEASES

#68
20210353683
2021-11-18

ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR

#69
20210340221
2021-11-04

KLK5 inhibitory peptide

#70
20210275541
2021-09-09

Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression

#71
20210268122
2021-09-02

INHIBITION OF SPONTANEOUS METASTASIS VIA PROTEIN INHIBITORS OF CYSTEINE PROTEASES

#72
20210238632
2021-08-05

VECTOR PRODUCTION IN SERUM FREE MEDIA

#73
20210236607
2021-08-05

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

#74
20210162030
2021-06-03

COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER WITH LEKTI

#75
20210162029
2021-06-03

COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI

#76
20210100827
2021-04-08

Combined administration of cysteine-aspartic protease inhibitors with P2Y12 receptor antagonists protects the heart against myocardial infarction

#77
20210077588
2021-03-18

Methods and compositions for treating diabetes

#78
20210060116
2021-03-04

Methods of reducing neuroinflammation or toxicity induced by amyloid beta (abeta) using glucocorticoid induced leucine zipper (GILZ) analog peptides

#79
20210060066
2021-03-04

COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTS

#80
20210025007
2021-01-28

Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA

#81
20200405829
2020-12-31

Circular strained zymogen compositions and methods of use

#82
20200390845
2020-12-17

Pharmaceutical formulations of C1 esterase inhibitor

#83
20200384062
2020-12-10

USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION

#84
20200360495
2020-11-19

METHODS OF TREATING ANTIBODY-MEDIATED REJECTION IN ORGAN TRANSPLANT PATIENTS WITH C1-ESTERASE INHIBITOR

#85
20200354407
2020-11-12

Peptide inhibitors of insulin-degrading enzyme

#86
20200338043
2020-10-29

Compositions and methods for treating allergic inflammatory conditions

#87
20200333024
2020-10-22

Compositions and methods for treatment of protease mediated disease

#88
20200316160
2020-10-08

Methods for the regulation of matrix metalloproteinase expression

#89
20200289747
2020-09-17

Device, system and methods for the oral delivery of therapeutic compounds

#90
20200289541
2020-09-17

Composition for ameliorating loss of hair and graying of hair, and use thereof

#91
20200254075
2020-08-13

Methods and compositions for treating aging-associated conditions

#92
20200239836
2020-07-30

Acellular placental preparations

#93
20200164051
2020-05-28

Compounds and methods for treatment and prevention of Flavivirus infection

#94
20200164049
2020-05-28

TREATMENT OF HUMAN METAPNEUMOVIRUS

#95
20200164026
2020-05-28

Intranasal Delivery of Cell Permeant Therapeutics

#96
20200147188
2020-05-14

THERAPEUTIC COMPOSITION CONTAINING ANTITHROMBIN GAMMA

#97
20200138913
2020-05-07

Formulations for oral administration of active agents

#98
20200131248
2020-04-30

Therapy using a factor XII inhibitor in a neurotraumatic disorder

#99
20200078442
2020-03-12

DPEP-1 binding compositions and methods of use

#100
20200038494
2020-02-06

Composition comprising highly-concentrated ALPHA1 proteinase inhibitor and method for obtaining thereof

#101
20190382745
2019-12-19

Methods and compositions for inhibiting ADAM 9 biological activities

#102
20190381130
2019-12-19

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

#103
20190374615
2019-12-12

Methods and Compositions for Treating Diabetes

#104
20190328852
2019-10-31

Methods for treatment of diseases

#105
20190262440
2019-08-29

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

#106
20190255158
2019-08-22

USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN

#107
20190248859
2019-08-15

Compositions comprising PEDF-derived short peptides and uses thereof

#108
20190247477
2019-08-15

Prevention and reduction of blood loss

#109
20190247444
2019-08-15

Egg protein formulations and methods of manufacture thereof

#110
20190247397
2019-08-15

Combinatory treatment strategies of cancer based on RNA polymerase I inhibition

#111
20190233472
2019-08-01

Tripeptides having angiotensin converting enzyme inhibitory activity and uses thereof

#112
20190224287
2019-07-25

Implantable matrix having optimum ligand concentrations

#113
20190219601
2019-07-18

Methods and kits for assessing Heparanase procoagulant activity, compositions comprising Heparanase, and methods for the treatment of coagulation-related disorders

#114
20190209655
2019-07-11

Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof

#115
20190142915
2019-05-16

OCULAR DELIVERY OF CELL PERMEANT THERAPEUTICS FOR THE TREATMENT OF RETINAL EDEMA

#116
20190142914
2019-05-16

Fusion proteins for treating inflammatory diseases

#117
20190134219
2019-05-09

INHIBITION OF SPONTANEOUS METASTASIS VIA PROTEIN INHIBITORS OF CYSTEINE PROTEASES

#118
20190105377
2019-04-11

METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES

#119
20190091247
2019-03-28

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

#120
20190022170
2019-01-24

Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same

#121
20190000915
2019-01-03

Methods for the regulation of matrix metalloproteinase expression

#122
20190000799
2019-01-03

Compositions and methods for treating allergic inflammatory conditions

#123
20180362616
2018-12-20

VARIANTS OF AMYLOID beta-PROTEIN PRECURSOR INHIBITOR DOMAIN

#124
20180355023
2018-12-13

TREATMENT OF DISEASE WITH LACTIC ACID BACTERIA HAVING STABLY INTEGRATED TRAPPIN-2

#125
20180353578
2018-12-13

Methods and compositions for treating aging-associated conditions

#126
20180333473
2018-11-22

Conjugated C1 Esterase Inhibitor and Uses Thereof

#127
20180325940
2018-11-15

Composition for ameliorating loss of hair and graying of hair, and use thereof

#128
20180319868
2018-11-08

Serpin reactive center loop peptides and methods of use

#129
20180318405
2018-11-08

Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies

#130
20180312541
2018-11-01

Dual-site BACE1 inhibitors

#131
20180258130
2018-09-13

D-amino acid compounds for liver disease

#132
20180256668
2018-09-13

Pharmaceutical composition for treatment of or remission in elderly or terminal cancer patient

#133
20180179252
2018-06-28

BACE1 inhibitor peptides

#134
20180104319
2018-04-19

METHODS OF TREATING ANTIBODY-MEDIATED REJECTION IN ORGAN TRANSPLANT PATIENTS WITH C1-ESTERASE INHIBITOR

#135
20180050096
2018-02-22

TREATMENT OF HYPOPARATHYROIDISM

#136
20180036394
2018-02-08

PHARMACEUTICAL FORMULATIONS OF C1 ESTERASE INHIBITOR

#137
20180036382
2018-02-08

FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE

#138
20180036375
2018-02-08

Spatiotemporal Delivery Vehicle and Related Methods

#139
20180022780
2018-01-25

STABILIZATION ADRENOMEDULLIN DERIVATIVES AND USE THEREOF

#140
20180021272
2018-01-25

Formulations for oral administration of active agents

#141
20180015153
2018-01-18

COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION

#142
20180009907
2018-01-11

NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES

#143
20180008771
2018-01-11

Device, system and methods for the oral delivery of therapeutic compounds

#144
20180008684
2018-01-11

COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN OR DERIVATIVES THEREOF

#145
20180000930
2018-01-04

Methods and Compositions for Preserving the Viability of Photoreceptor Cells

#146
20170369841
2017-12-28

Method for modifying T cell population

#147
20170368136
2017-12-28

Compositions and methods for CaMKII inhibitors and uses thereof

#148
20170368050
2017-12-28

Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

#149
20170360905
2017-12-21

Conjugated C1 Esterase Inhibitor and Uses Thereof

#150
20170360873
2017-12-21

Modulation and detection of a neuronal alternative splicing regulatory network for treatment and diagnosis of neurological disorders

#151
20170354723
2017-12-14

Compositions and methods for cell transplantation

#152
20170326199
2017-11-16

USE OF CASPASE-2 INHIBITORS TO TREAT AND PREVENT THE METABOLIC SYNDROME

#153
20170281716
2017-10-05

Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing

#154
20170260230
2017-09-14

Compounds for enzyme inhibition

#155
20170258872
2017-09-14

DPEP-1 binding compositions and methods of use

#156
20170253646
2017-09-07

Functional Peptide Analogs of PEDF

#157
20170216416
2017-08-03

Pigment epithelium-derived factor (PEDF) and peptide derivatives thereof for use in osteoblast differentiation and bone growth

#158
20170190737
2017-07-06

Macrocyclic inhibitors of flaviviridae viruses

#159
20170114119
2017-04-27

THERAPY USING A FACTOR XII INHIBITOR IN A NEUROTRAUMATIC DISORDER

#160
20170042940
2017-02-16

Compositions and methods for cell transplantation

#161
20160361395
2016-12-15

Prevention and reduction of blood loss

#162
20160334425
2016-11-17

Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation related disorders

#163
20160303194
2016-10-20

Compositions and method for treatment of inflammatory bowel disease

#164
20160303187
2016-10-20

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

#165
20160250292
2016-09-01

In vivo individualized systemic immunotherapeutic method and device

#166
20160228520
2016-08-11

Compositions and methods for treating granulomatosis with polyangiitis

#167
20160213738
2016-07-28

Cardiovascular disease treatment and prevention

#168
20160199444
2016-07-14

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

#169
20160151445
2016-06-02

Methods for the regulation of matrix metalloproteinase expression

#170
20160136248
2016-05-19

Methods and materials for treating cancers that express reduced levels of wild-type p53 polypeptides

#171
20160101120
2016-04-14

Method for producing a mixture of neutral oligosaccharides extracted from flaxseed

#172
20160068580
2016-03-10

Method for treatment of GM1 gangliosidosis

#173
20160058876
2016-03-03

Polyplexes

#174
20160051593
2016-02-25

Egg protein formulations and methods of manufacture thereof

#175
20160008422
2016-01-14

Compositions and methods for CaMKII inhibitors and uses thereof

#176
20150366940
2015-12-24

Serpins: methods of therapeutic β-cell regeneration and function

#177
20150335715
2015-11-26

METHODS AND COMPOSITIONS FOR TREATING NAFLD, HEPATIC STEATOSIS, AND SEQUELAE THEREOF

#178
20150316552
2015-11-05

Human Notch Receptor Mutations and Their Use

#179
20150274774
2015-10-01

Macrocyclic inhibitors of flaviviridae viruses

#180
20150239955
2015-08-27

Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof

#181
20150147319
2015-05-28

Methods of treating antibody-mediated rejection in organ transplant patients with C1-esterase inhibitor

#182
20150132296
2015-05-14

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

#183
20150079094
2015-03-19

Functional peptide analogs of PEDF

#184
20150038530
2015-02-05

Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

#185
20150038432
2015-02-05

Compositions and methods for the treatment of retinal degeneration

#186
20150031603
2015-01-29

Macrocyclic compounds for suppressing replication of hepatitis C virus

#187
20150023981
2015-01-22

Method of treatment and agents useful for same

#188
20150017238
2015-01-15

Methods and compositions for treating diabetes

#189
20150017237
2015-01-15

Dosage form comprising lopinavir and ritonavir

#190
20140378653
2014-12-25

Factor XII inhibitors for the treatment of neurological inflammatory disorders

#191
20140349940
2014-11-27

Prevention and reduction of blood loss

#192
20140341861
2014-11-20

Rapid infusion of autologous bone marrow derived stem cells

#193
20140329742
2014-11-06

Peptide YY analogs

#194
20140308243
2014-10-16

Hepatitis C virus inhibitors

#195
20140288001
2014-09-25

Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

#196
20140286870
2014-09-25

Rapid infusion of autologous bone marrow derived stem cells

#197
20140286869
2014-09-25

Rapid infusion of autologous bone marrow derived stem cells

#198
20140243255
2014-08-28

Treatments for

#199
20140234302
2014-08-21

Methods and compositions for reducing amyloid beta levels

#200
20140234293
2014-08-21

Combination therapy using immunoglobulin and C1-Inhibitor

#201
20140221927
2014-08-07

Device, system and methods for the oral delivery of therapeutic compounds

#202
20140220141
2014-08-07

Compositions of lopinavir and ritonavir

#203
20140199289
2014-07-17

Use of matrix metalloproteinase inhibitors to treat tuberculosis

#204
20140178472
2014-06-26

Methods of regulating glucose metabolism, and reagents related thereto

#205
20140142029
2014-05-22

Macrocyclic broad spectrum antibiotics

#206
20140140977
2014-05-22

Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation related disorders

#207
20140107042
2014-04-17

Method for ameliorating radiation exposure effects with alpha-1 antitrypsin

#208
20140073588
2014-03-13

GLUE COMPOSITION FOR LUNG VOLUME REDUCTION

#209
20140051641
2014-02-20

Compounds for enzyme inhibition

#210
20140050737
2014-02-20

Compounds for enzyme inhibition

#211
20140031297
2014-01-30

Compounds for enzyme inhibition

#212
20130344029
2013-12-26

Macrocyclic inhibitors of flaviviridae viruses

#213
20130330358
2013-12-12

CRYSTAL STRUCTURE AND PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE

#214
20130310305
2013-11-21

Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis

#215
20130302291
2013-11-14

COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION

#216
20130267441
2013-10-10

Biomarker and uses thereof in diagnosis, treatment of autism

#217
20130252920
2013-09-26

Pharmaceutical combinations comprising a thionucleotide analog

#218
20130210778
2013-08-15

Formulation for the prevention of cardiovascular disease

#219
20130172232
2013-07-04

Cysteine protease inhibitors

#220
20130156785
2013-06-20

NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES

#221
20130095108
2013-04-18

Factor XII inhibitors for treating interstitial lung disease

#222
20130084310
2013-04-04

Compositions and methods for platelet enriched fibrin constructs

#223
20130046283
2013-02-21

METHODS AND INTRAVASCULAR TREATMENT DEVICES FOR TREATMENT OF ATHEROSCLEROSIS

#224
20130045216
2013-02-21

Method for treating amyloid disease

#225
20130040899
2013-02-14

Use of PEDF-derived polypeptides for treating liver cirrhosis

#226
20130022611
2013-01-24

METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR

#227
20130017601
2013-01-17

MODULATION OF PLASMA MEMBRANE HUMAN LEUKOCYTE ELASTASE

#228
20130012438
2013-01-10

Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

#229
20120289452
2012-11-15

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NECROSIS

#230
20120237480
2012-09-20

2′allene-substituted nucleoside derivatives

#231
20120208995
2012-08-16

Macrocyclic inhibitors of hepatitis C virus replication

#232
20120171192
2012-07-05

Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides

#233
20120165252
2012-06-28

Method of regulating glucose metabolism, and reagents related thereto

#234
20120148688
2012-06-14

PREVENTION OF THROMBUS FORMATION AND/OR STABILIZATION

#235
20110251136
2011-10-13

Glue composition for lung volume reduction

#236
20110250172
2011-10-13

Hepatitis C virus inhibitors

#237
20110245150
2011-10-06

TARGETS FOR TREATMENT OF CHLAMYDIAL INFECTIONS

#238
20110230396
2011-09-22

ANTI-INFECTIVE COMPOUNDS AND USES THEREOF

#239
20110172149
2011-07-14

Method of regulating glucose metabolism, and reagents related thereto

#240
20110159004
2011-06-30

Methods and Compositions for Preserving the Viability of Photoreceptor Cells

#241
20110142797
2011-06-16

Method for prophylaxis or treatment of feline infectious peritonitis

#242
20110104146
2011-05-05

Method of inhibiting platelet aggregation and clot formation

#243
20110086801
2011-04-14

Prevention and reduction of blood loss

#244
20110059896
2011-03-10

USE OF FURIN CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING

#245
20110046063
2011-02-24

READY-TO-USE BIVALIRUDIN COMPOSITIONS

#246
20100329664
2010-12-30

SHUTTER DEVICE FOR CAMERA

#247
20100323968
2010-12-23

Process of inhibiting cell death in injured cartilage

#248
20100316607
2010-12-16

Hepatitis C virus inhibitors

#249
20100292165
2010-11-18

Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation

#250
20100272709
2010-10-28

Cathepsin L mediated diseases and associated methods and products

#251
20100267635
2010-10-21

USE OF PROTEASE INHIBITORS AND GRF MOLECULES IN COMBINATION THERAPY

#252
20100266698
2010-10-21

USE OF INSULIN FOR THE TREATMENT OF CARTILAGINOUS DISORDERS

#253
20100247635
2010-09-30

Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same

#254
20100240584
2010-09-23

Nematode-extracted serine protease inhibitors and anticoagulant proteins

#255
20100226882
2010-09-09

Linked diimidazole antivirals

#256
20100221317
2010-09-02

Dynamin mediated diseases and associated methods and products

#257
20100216875
2010-08-26

METHODS OF TREATING ALZHEIMER'S DISEASE

#258
20100204683
2010-08-12

Therapeutic hybrid implantable devices

#259
20100095387
2010-04-15

METHODS AND REAGENTS FOR SCREENING NEW DRUGS AND FOR TREATING ION PUMP ASSOCIATED DISORDERS AND DISEASES

#260
20100092409
2010-04-15

Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors

#261
20100068260
2010-03-18

Methods, Compositions and Device for Directed and Controlled Heating and Release of Agents

#262
20100061996
2010-03-11

METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR

#263
20100040612
2010-02-18

Methods and compositions for reducing amyloid beta levels

#264
20100021505
2010-01-28

Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients

#265
20090318534
2009-12-24

METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND DISORDERS

#266
20090318351
2009-12-24

METHOD OF TREATING ACUTE ST-ELEVATION MYOCARDIAL INFARCTION WITH A DELTA PKC ANTAGONIST

#267
20090312260
2009-12-17

DRUG THERAPY FOR CELIAC SPRUE

#268
20090269331
2009-10-29

Caspase-8 and inflammation, infection and wound healing

#269
20090264350
2009-10-22

Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

#270
20090247453
2009-10-01

Kallikrein Inhibitors and Anti-thrombolytic Agents and Uses Thereof

#271
20090234009
2009-09-17

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#272
20090233852
2009-09-17

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#273
20090232866
2009-09-17

Oligopeptides as coating material for medical products

#274
20090232793
2009-09-17

Elastase inhibitor and acute leukemia

#275
20090227495
2009-09-10

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#276
20090227494
2009-09-10

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#277
20090221480
2009-09-03

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#278
20090221472
2009-09-03

Method for treating transplant rejection

#279
20090214464
2009-08-27

COMPOUNDS FOR FLAVIVIRIDAE TREATMENT

#280
20090203698
2009-08-13

Compounds for enzyme inhibition

#281
20090186827
2009-07-23

Process of inhibiting cell death in injured cartilage

#282
20090175853
2009-07-09

Method for treating amyloid disease

#283
20090169510
2009-07-02

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

#284
20090148407
2009-06-11

Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication

#285
20090104183
2009-04-23

Glue composition for lung volume reduction

#286
20090082309
2009-03-26

Method of regulating glucose metabolism, and reagents related thereto

#287
20090082267
2009-03-26

Prevention and reduction of blood loss

#288
20090081183
2009-03-26

HIV Transcription Repressor Complex and Compositions and Methods Based Thereon

#289
20090060897
2009-03-05

System comprising elastase

#290
20080260752
2008-10-23

PREVENTION AND REDUCTION OF BLOOD LOSS

#291
20080254039
2008-10-16

Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII

#292
20080221031
2008-09-11

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#293
20080219998
2008-09-11

Anti-Thrombotic Agents

#294
20080206219
2008-08-28

Novel Indications for Transforming Growth Factor-Beta Regulators

#295
20080200646
2008-08-21

Prevention and reduction of blood loss

#296
20080194485
2008-08-14

Detection and Use of Prolylcarboxypeptidase

#297
20080188409
2008-08-07

Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof

#298
20080152656
2008-06-26

PREVENTION AND REDUCTION OF BLOOD LOSS

#299
20080131426
2008-06-05

Prevention and Reduction of Blood Loss

#300
20080090766
2008-04-17

Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient